ArticleInternational journal of clinical and experimental pathology2018
Clinical significance of PD-L1 (CD274) enhanced expression in cervical squamous cell carcinoma.
Article in International journal of clinical and experimental pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Predictive Values of Programmed Cell Death-Ligand 1 Expression for Prognosis, Clinicopathological Factors, and Response to Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors in Patients With Gynecological Cancers: A Meta-Analysis.Frontiers in oncology · 2020Pooled it
- Expression of Programmed Death-Ligand 1 in Cervical Cancer: Correlation With Histologic Subtypes and Clinicopathological Features.Immunity, inflammation and disease · 2026Article
- Systems Analysis of miRNA-Mediated Host Regulatory Response in HPV-Associated Cervical Malignancy.Computational and structural biotechnology journal · 2026Article
- Clinical Efficacy and Safety of Pembrolizumab-Based Therapy in Recurrent or Advanced Cervical Cancer: A Systematic Review and Meta-Analysis.OncoTargets and therapy · 2026Review
- PD-L1 expression in squamous cervical carcinomas of Mozambican women living with or without HIV.Scientific reports · 2024Article
- Unraveling Differences in Molecular Mechanisms and Immunological Contrasts between Squamous Cell Carcinoma and Adenocarcinoma of the Cervix.International journal of molecular sciences · 2024Article
- The molecular evolution of cancer associated genes in mammals.Scientific reports · 2024Article
- Programmed death-ligand 1 (PD-L1) expression in cervical intraepithelial neoplasia and cervical squamous cell carcinoma of HIV-infected and non-infected patients.Virchows Archiv : an international journal of pathology · 2024Article
- Expression profile of miRNAs computationally predicted to target PDL-1 in cervical tissues of different histology groups.Frontiers in cell and developmental biology · 2023Review
- Moesin Serves as Scaffold Protein for PD-L1 in Human Uterine Cervical Squamous Carcinoma Cells.Journal of clinical medicine · 2022Article
- The effect of Wnt/β-catenin signaling on PD-1/PDL-1 axis in HPV-related cervical cancer.Oncology research · 2022Review
- Programme death ligand 1 expressions as a surrogate for determining immunotherapy in cervical carcinoma patients.PloS one · 2022Article
- EphA2 Promotes the Development of Cervical Cancer through the CXCL11/PD-L1 Pathway.Journal of oncology · 2022Article
- Increased expression of TAZ and associated upregulation of PD-L1 in cervical cancer.Cancer cell international · 2021Article
- Prognostic and therapeutic TILs of cervical cancer-Current advances and future perspectives.Molecular therapy oncolytics · 2021Review
- Targeting the PD-1 Axis with Pembrolizumab for Recurrent or Metastatic Cancer of the Uterine Cervix: A Brief Update.International journal of molecular sciences · 2021Review
- Elevated PD-L1 expression predicts poor survival outcomes in patients with cervical cancer.Cancer cell international · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Programmed death ligand 1 (PD-L1) is a trans-membrane protein that can reduce the immune response in both infectious diseases and cancers and is commonly expressed in various solid tumors. Despite the success of immunotherapy directed at inhibiting of PD-L1/PD-1 signaling, it is not established that whether PD-L1 expression correlates with the clinical response and outcome in cervical squamous cell carcinoma. To investigate the clinical significance of PD-L1 expression in cervical cancer, we analyzed the expression of PD-L1 in 219 cervical squamous cell cancers and 30 healthy controls,characterized the expression level of PDL-1 in tumor-infiltrating lymphocytes (TILs), and assessed the relationship between them and prognosis of cervical cancers. The expression of PD-L1 was observed in 32.4% (71/219) cervical carcinomas and 10.0% (22/219) in partial TILs. However, there was no expression of PD-L1 in normal cervical epithelium. Statistical analysis showed that increased PD-L1 expression was significantly associated with high TNM stage, reduced number of TILs, and worse prognosis in cervical carcinomas, but there was no significant statistic difference in age, tumor size, HPV infection and other clinicopathology features. PD-L1 expression in TILs was found significantly associated with the TILs amount. Furthermore, the presence of prominent lymphocytic infiltrates was also significantly associated with a clear trend towards longer survival. In conclusion, these data suggested that PD-L1 could act as a significant biomarker in the worse prognosis and adverse clinicopathologic features of cervical cancer. Anti-PD-L1 therapy may have a role in the treatment of cervical squamous cell carcinoma.
Indexed as
Identifiers
31949618PMC6963033W3005060426What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.